  | Polese, B., Ernst, M., Henket, M., Ernst, B., Winandy, M.-L., Njock, M.-S., BLOCKX, C., KOVACS, S., WATAR, F., Peired, A. J., Tomassetti, S., Nardi, C., Gofflot, S., Rahmouni, S., Schofield, J. P., Penrice-Randa, R., Skipp, P. J., Strazzeri, F., Parkinson, E., ... Guiot, J. (2024). Circulating inflammatory cytokines predict severity disease in hospitalized COVID-19 patients: a prospective multicenter study of the European DRAGON consortium. Journal of Infection and Public Health, 102589. doi:10.1016/j.jiph.2024.102589  Peer Reviewed verified by ORBi |
 | Ladang, A., GENDEBIEN, A.-S., KOVACS, S., Demonceau, C., Beaudart, C., Peeters, S., Alokail, M. S., Al-Daghri, N., Le Goff, C., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (24 September 2024). Investigation of the Vitamin D Metabolite Ratio (VMR) as a Marker of Functional Vitamin D Deficiency: Findings from the SarcoPhAge Cohort. Nutrients, 16 (19), 3224. doi:10.3390/nu16193224 Peer Reviewed verified by ORBi |
 | Ladang, A., GENDEBIEN, A.-S., KOVACS, S., Demonceau, C., Beaudart, C., Le Goff, C., Reginster, J.-Y., Bruyère, O., Al-Daghri, N., Alokail, M. S., & Cavalier, E. (2024). Vitamin D metabolite ratio (VMR) offers the best approach to evaluate functional vitamin D deficiency: results of the Sarcophage study. Aging Clinical and Experimental Research. Peer Reviewed verified by ORBi |
 | Ladang, A., KOVACS, S., Lengele, L., Locquet, M., Beaudart, C., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (October 2023). Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study. Aging Clinical and Experimental Research, 35 (10), 2029 - 2037. doi:10.1007/s40520-023-02521-9 Peer Reviewed verified by ORBi |
 | LADANG, A., KOVACS, S., Lengele, L., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (2022). Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in sarcopenic patients: results of the sarcophage study. Osteoporosis International, 32 (Suppl 1), 53. Peer Reviewed verified by ORBi |
  | LADANG, A., ROUSSELLE, O., Huyghebaert, L., BEKAERT, A.-C., KOVACS, S., Le Goff, C., & Cavalier, E. (2020). Parathormone, bone alkaline phosphatase and 25-hydroxyvitamin D status in a large cohort of 1200 children and teenagers. Acta Clinica Belgica, 1-6. doi:10.1080/17843286.2020.1769285 Peer Reviewed verified by ORBi |
 | Cavalier, E., Huyghebaert, L., ROUSSELLE, O., BEKAERT, A.-C., KOVACS, S., VRANKEN, L., PEETERS, S., Le Goff, C., & LADANG, A. (2020). Simultaneous measurement of 25(OH)-vitamin D and 24,25(OH)2-vitamin D to define cut-offs for CYP24A1 mutation and vitamin D deficiency in a population of 1200 young subjects. Clinical Chemistry and Laboratory Medicine, 58 (2), 197-201. doi:10.1515/cclm-2019-0996 Peer Reviewed verified by ORBi |
 | LADANG, A., ROUSSELLE, O., Huyghebaert, L., BEKAERT, A.-C., KOVACS, S., LE GOFF, C., & CAVALIER, E. (May 2019). 24,25(OH)2D AS A MARKER OF VITAMIN D DEFICIENCY IN CHILDREN: A RETROSPECTIVE [Poster presentation]. Euromedlab 2019. |
 | LADANG, A., ROUSSELLE, O., Huyghebaert, L., BEKAERT, A.-C., KOVACS, S., LE GOFF, C., & CAVALIER, E. (May 2019). EVALUATION OF PARATHORMONE AND 25-HYDROXYVITAMIN D STATUS IN A LARGE [Poster presentation]. Euromedlab 2019. |
 | LADANG, A., ROUSSELLE, O., BEKAERT, A.-C., KOVACS, S., & CAVALIER, E. (May 2019). PEDIATRIC REFERENCE INTERVALS FOR BONE ALKALINE PHOSPHATASE ON LIAISON° XL [Poster presentation]. Euromedlab 2019. |
CAVALIER, E., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (16 April 2016). Evaluation of the intra-individual variability of Myostatin and Activin A (and PIIINP): impact on the least significant change and follow-up of the patients [Paper presentation]. World Congresse on Osteoporosis Osteoarthritis and musculoskeletal diseases, Malaga, Spain. |
 | CAVALIER, E., Piron, C., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (April 2016). Evaluation of the intra-individual variability of myostatin and activin A, two biomarkers of sarcopenia: impact on the least significant change and followup of the patients. Osteoporosis International, 27 (supplement 1), 56. Peer Reviewed verified by ORBi |
 | CAVALIER, E., CARLISI, I., KOVACS, S., WATAR, F., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (April 2016). Brain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations. Osteoporosis International, 27 (Supplement 1), 512. Peer Reviewed verified by ORBi |
 | CAVALIER, E., Piron, C., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (2016). Evaluation of the intra-individual variability of myostatin and activin A, two biomarkers of sarcopenia. Impact of the least significant change and follow-up of the patients. Journal of Frailty and Aging, 5 (Supplement 1), 82. Peer reviewed |
 | CAVALIER, E., Carlisi, A. S., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (2016). Brain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations. Journal of Frailty and Aging, 5 (Supplement 1), 116. Peer reviewed |
